Navigation Links
Watson Launches Generic Biaxin(R) XL
Date:1/3/2008

CORONA, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg strength. Watson's Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R) XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. For the 12-months ending September 2007, Biaxin(R) XL and its generic equivalents had total U.S. sales of approximately $200 million, according to IMS Health data.

The U.S. Food and Drug Administration granted final approval of Watson's Abbreviated New Drug Application (ANDA) for Clarithromycin Extended-Release on June 24, 2004. Patent infringement litigation related to Watson's ANDA was dismissed with prejudice on July 12, 2007.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as o
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
2. APIC Launches Targeting Zero Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS
3. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
4. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
5. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
6. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
7. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
10. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...AN DIEGO, Nov. 25 NuVasi...y focused on developing products for minimally dis...ed today that it will host a conference call on Mo...m. PT. The conference call will focus on current ... products and will include comments from managemen...
(Date:11/25/2009)... YORK, Nov. 25 Reportlinker.com an...able in its catalogue: ,, Pain Management - G...p0164220/Pain-Management---Global-Trends.html ,...ence of pain management clinics, and the advent of...the pain management market. Healthcare reforms and...
(Date:11/25/2009)...LFT, The Netherlands and JOHANNESBURG, November 25...division and Pyxis Discovery announced today,that ...tly market both,companies, services. , Py... discovery expertise,will be coupled with iThemba,...tic chemistry support to projects identified throu...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Gazelle Launches Technology for Tots Fundraising Campaign with SHARED Inc 54056 1Gazelle Launches Technology for Tots Fundraising Campaign with SHARED Inc 54056 2Gazelle Launches Technology for Tots Fundraising Campaign with SHARED Inc 54056 3First Ever Downloadable Safety in the Home Guides Available Now From VisionAWARE org 54051 1First Ever Downloadable Safety in the Home Guides Available Now From VisionAWARE org 54051 2Enobia Raises US 2450M from Current Investors in Series C Financing 13472 1Enobia Raises US 2450M from Current Investors in Series C Financing 13472 2Enobia Raises US 2450M from Current Investors in Series C Financing 13472 3
...atment Benefits Were Maintained for at Least 24 We...of Urology, LONDON, May 15, 2007 /PRNewswire/ -- R...London School of Medicine have,announced the resul...o-controlled study evaluating botulinum toxin type... detrusor overactivity (IDO),in patients with symp...
...EIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - Salix,...d that results of,18 investigator-initiated trials...ed at Digestive Disease Week(R) 2007, which will b...considered the,largest and most prestigious meetin... it attracts more than 16,000 physicians,research...
Other Medicine Technology:First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 2First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 3First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:11/27/2009)...d cycling plus low-emission vehicles may reduce fu... FRIDAY, Nov. 27 (HealthDay News) -- Encouraging c...cars would offer much greater public health benefi....K. researchers have found. , The study compare...ive urban land transport scenarios for London, Eng...
(Date:11/27/2009)... Voyant Health™ announced tod...as licensed its TraumaCad Enterprise orthopedic te...w solution. , (PRWEB) Nov...oday that Spectrum Health (Grand Rapids, Michigan)...templating solution and its TraumaCad Extend workf...
(Date:11/27/2009)... Three new interactive anatomy educ...amp; Wilkins expand health sciences learning oppor... Durham, NC (Vocus) November 27, 2009 -...ilkins (LWW), a division of Wolters Kluwer Health,...tomy education apps on the App Store. Clemente&rsq...
(Date:11/26/2009)...ext 25 years, the number of Americans living with ...million in 2009 to 44.1 million in 2034. Over the ...le, rising from $113 billion to $336 billion, even...searchers based at the University of Chicago repor...e number of those with diabetes covered by Medicar...
(Date:11/26/2009)... bigger thrill when on an emotional rollercoaster,...thDay News) -- Call it the fear factor meets the j... spectators -- especially those who root for the w...it,s a closely contested match and victory was in ...r. , Chew on that this Thanksgiving weekend as ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
...a., Nov. 4 NeoGenomics, Inc.,(OTC Bulletin Board:...s,third quarter 2008 financial results on Thursday...ebcast and conference call to discuss,their Q3 08 ...ive minutes prior to the call. A replay of the,con...
...rs stress absolute chances of disease are still sm...- Women with silicone breast implants may have a h...new research suggests. , But the absolute risk of ...dy published in the Nov. 5 issue of the Journal o...
... 4 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmace...r the "Company"), a,pharmaceutical company in the ...d that it will present at the upcoming Rodman & Re...s, presentation at the,conference are: Date: ...
...nk Sees Significant Benefits from Next-Generation ...OTHELL, Wash., Nov. 4 BioLife Solutions,Inc. (OTC...rketer of,proprietary hypothermic storage and cryo...ks International, a,Florida-based cord blood stem ...
...s at the University of Virginia Health System repo...onal drug, MK-677, increased muscle mass in the ar...s side effects, suggesting that it may prove safe ...ls of growth hormone (GH) and of insulin-like grow...
...te (MTX) is commonly used to treat rheumatoid arth...n treating the disease. Despite its widespread use... pharmacokinetics is limited. Since joint damage o... effectively controlling RA and preventing long-te...
Other Medicine News:Health News:NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008 2Health News:Silicone Breast Implants Might Raise Risk of Rare Lymphoma 2Health News:Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference 2Health News:BioLife Solutions to Supply CryoStor(TM) to Cryobanks International as Standard Media for Preservation and Storage of Umbilical Cord Blood Stem Cells 2Health News:BioLife Solutions to Supply CryoStor(TM) to Cryobanks International as Standard Media for Preservation and Storage of Umbilical Cord Blood Stem Cells 3Health News:BioLife Solutions to Supply CryoStor(TM) to Cryobanks International as Standard Media for Preservation and Storage of Umbilical Cord Blood Stem Cells 4Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 2Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 3
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: